Artículos por temáticas

A review of neuroimaging-based data-driven approach for Alzheimer's disease heterogeneity analysis

Liu L, Sun S, Kang W, Wu S, Lin L.

Rev Neurosci. 2023 Jul 10;35(2):121-139. doi: 10.1515/revneuro-2023-0033. Print 2024 Feb 26.

Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's disease

Shukla AK, Misra S.

J Basic Clin Physiol Pharmacol. 2023 Dec 6;35(1-2):25-29. doi: 10.1515/jbcpp-2023-0176. eCollection 2024 Jan 1.

Exosomes for the diagnosis and treatment of dementia

Joo HS, Jeon HY, Hong EB, Kim HY, Lee JM.

Curr Opin Psychiatry. 2023 Mar 1;36(2):119-125. doi: 10.1097/YCO.0000000000000842. Epub 2023 Jan 11.

Glutathione-Mediated Neuroprotective Effect of Purine Derivatives

Matsumura N, Aoyama K.

Int J Mol Sci. 2023 Aug 22;24(17):13067. doi: 10.3390/ijms241713067.

Therapeutic considerations of bioactive compounds in Alzheimer's disease and Parkinson's disease: Dissecting the molecular pathways

Phukan BC, Roy R, Gahatraj I, Bhattacharya P, Borah A.

Phytother Res. 2023 Dec;37(12):5657-5699. doi: 10.1002/ptr.8012. Epub 2023 Oct 12.

Kaempferol, a potential neuroprotective agent in neurodegenerative diseases: From chemistry to medicine

Jin S, Zhang L, Wang L.

Biomed Pharmacother. 2023 Sep;165:115215. doi: 10.1016/j.biopha.2023.115215. Epub 2023 Jul 24.

Role of Bmal1 and Gut Microbiota in Alzheimer's Disease and Parkinson's Disease Pathophysiology: The Probable Effect of Melatonin on Their Association

Khezri MR, Esmaeili A, Ghasemnejad-Berenji M.

ACS Chem Neurosci. 2023 Nov 1;14(21):3883-3893. doi: 10.1021/acschemneuro.3c00418. Epub 2023 Oct 12.

Docosahexaenoic acid inhibits ischemic stroke to reduce vascular dementia and Alzheimer's disease

Yamagata K.

Prostaglandins Other Lipid Mediat. 2023 Aug;167:106733. doi: 10.1016/j.prostaglandins.2023.106733. Epub 2023 Apr 5.

Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias

Perlett L, Smith EE.

Clin Geriatr Med. 2023 Feb;39(1):135-149. doi: 10.1016/j.cger.2022.07.008. Epub 2022 Oct 18.

Beyond "Psychotropic": Repurposing Psychiatric Drugs for COVID-19, Alzheimer's Disease, and Cancer

Lenze EJ, Reiersen AM, Zorumski CF, Santosh PJ.

J Clin Psychiatry. 2023 Mar 20;84(3):22r14494. doi: 10.4088/JCP.22r14494.

Natural Products as the Potential to Improve Alzheimer's and Parkinson's Disease

Kim SW, Lee JH, Kim B, Yang G, Kim JU.

Int J Mol Sci. 2023 May 16;24(10):8827. doi: 10.3390/ijms24108827.

Advances in the Application of Induced Pluripotent Stem Cells in Alzheimer's Disease and Parkinson's Disease

Xu Y, Wang S, Zhu P.

Curr Stem Cell Res Ther. 2023;18(2):154-162. doi: 10.2174/1574888X17666220426114050.

Crosstalk between Alzheimer's disease and diabetes: a focus on anti-diabetic drugs

Goodarzi G, Tehrani SS, Fana SE, Moradi-Sardareh H, Panahi G, Maniati M, Meshkani R.

Metab Brain Dis. 2023 Aug;38(6):1769-1800. doi: 10.1007/s11011-023-01225-3. Epub 2023 Jun 19.

Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease

Nowell J, Blunt E, Edison P.

Mol Psychiatry. 2023 Jan;28(1):217-229. doi: 10.1038/s41380-022-01792-4. Epub 2022 Oct 18.

miRNAs and Stem Cells as Promising Diagnostic and Therapeutic Targets for Alzheimer's Disease

Elzayat EM, Shahien SA, El-Sherif AA, Hosney M.

J Alzheimers Dis. 2023;94(s1):S203-S225. doi: 10.3233/JAD-221298.